EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC

The purpose of this study is to see if study drug XL092 alone or in combination with nivolumab can treat your cancer after your cancer has progressed on adjuvant treatment. Researchers also want to look at the safety of the XL092 alone and in combination with nivolumab. We are asking you to take part in this research study because you have clear cell renal cell carcinoma (clear cell kidney cancer), and your disease has come back after adjuvant treatment (treatment given after your disease progresses from your first treatment). - XL092 is not approved by the U.S. Food and Drug Administration (FDA) to treat any type of cancer. - Nivolumab is approved by the FDA to treat renal cell carcinoma and other types of cancer. Its use in this study is investigational and not approved by the FDA. - Giving the XL092 alone or in combination with nivolumab is considered investigational.

Are you Eligible? (Inclusion Criteria)

• Age ≥ 18 years at the time of consent. - Measurable disease. - ECOG Performance Status of 0-1 within 28 days prior to registration - Prior cancer treatment must have included an anti-PD-1/L1. - Advanced or metastatic renal cell carcinoma with a clear cell component.